Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavrilimumab - CSL/Kiniksa Pharmaceuticals

Drug Profile

Mavrilimumab - CSL/Kiniksa Pharmaceuticals

Alternative Names: Anti-GM-CSFR monoclonal antibody - MedImmune; CAM-3001; KPL-301

Latest Information Update: 08 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zenyth Therapeutics
  • Developer Kiniksa Pharmaceuticals; MedImmune
  • Class Anti-inflammatories; Antirheumatics; Antivirals; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Granulocyte-macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell arteritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Inflammation; Pneumonia
  • Phase II Giant cell arteritis
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 06 Oct 2020 Kiniksa Pharmaceuticals plans a meeting with US FDA for Giant cell arteritis
  • 06 Oct 2020 Adverse event and efficacy data from a phase II trial in Giant cell arteritis released by Kiniksa
  • 15 Sep 2020 Mavrilimumab receives Orphan Drug status for Giant cell arteritis in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top